Overexpression of Special AT-Rich Sequence-Binding Protein 1 in Endometrial Cancer: A Clinicopathologic Study
OBJECTIVESpecial AT-rich sequence-binding protein 1 (SATB1), as a genome organizer, serves important functions in tumor progression and metastasis. The SATB1 is overexpressed in various malignant tumors. However, the expression and prognostic value of SATB1 in endometrial cancer remain unknown. The...
Gespeichert in:
| Veröffentlicht in: | International journal of gynecological cancer 2015-01, Vol.25 (1), p.4-11 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 11 |
|---|---|
| container_issue | 1 |
| container_start_page | 4 |
| container_title | International journal of gynecological cancer |
| container_volume | 25 |
| creator | Zhang, Yu Wang, Le Liu, Yunduo Meng, Fanling Wang, Shuxiang Shang, Pan Gao, Ya Chen, Xiuwei |
| description | OBJECTIVESpecial AT-rich sequence-binding protein 1 (SATB1), as a genome organizer, serves important functions in tumor progression and metastasis. The SATB1 is overexpressed in various malignant tumors. However, the expression and prognostic value of SATB1 in endometrial cancer remain unknown. The aim of this study was to explore the prognostic values of SATB1 expression in endometrial cancer.
METHODS/MATERIALSWe investigated the expression of SATB1 in 172 untreated endometrial cancer tissues and 25 normal endometrial tissues through immunohistochemical staining. We also analyzed the association of SATB1 level with clinicopathologic parameters and determined its prognostic significance.
RESULTSpecial AT-rich sequence-binding protein 1 was expressed in 78 (45.3%) of the 172 endometrial cancer samples, but not in the normal endometrial samples. The positive expression of SATB1 was associated with clinicopathologic factors, such as International Federation of Gynecology and Obstetrics stage, histological grade, myometrial invasion depth, lymph node metastasis, vascular/lymphatic invasion, and recurrence. The patients with positive SATB1 expression had worse overall survival and disease-free survival rates than the patients with negative SATB1 expression (P < 0.001 for both). Multivariate Cox analysis indicated that SATB1 was an independent parameter for overall survival (hazards ratio, 2.928; 95% confidence interval, 1.072–7.994; P = 0.036) and disease-free survival (hazards ratio, 2.825; 95% confidence interval, 1.111–7.181; P = 0.029).
CONCLUSIONSResults showed that SATB1 may be involved in tumor development and progression in endometrial cancer, may serve as a promising biomarker for predicting the prognosis of endometrial cancer patients, and thus may act as a novel target for treating endometrial carcinoma. |
| doi_str_mv | 10.1097/IGC.0000000000000314 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_1639497362</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2552839546</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3394-6be09afa9424a433b0dc883cd6849f452570fcb8dd3533c91a2d67858fbaa5b13</originalsourceid><addsrcrecordid>eNpdkU1PHSEUhklTU632HxhD0o2bURhgBtxdJ9aamGi8mnRHGGC8KAMjzNT674vRJo1ncc5ZPOfzBWAfoyOMRHt8cd4dof-NYPoJ7GBWswpTwj-XHFFecYF_bYOvOT8URtRIfAHbNSO0RaLZAePVb5vsnynZnF0MMA5wPVntlIer2-rG6Q1c26fFBm2rUxeMC_fwOsXZugAxLO4smDjaOb1WdKpg6QSuYOddcDpOat5EH--dhut5MS97YGtQPttv73EX3P04u-1-VpdX5xfd6rLShAhaNb1FQg1K0JoqSkiPjOacaNNwKgZaLmzRoHtuDGGEaIFVbZqWMz70SrEek11w-NZ3SrEsn2c5uqyt9yrYuGSJmzJGtKSpC_r9A_oQlxTKdrJmrOZEMNoU6uCdWvrRGjklN6r0Iv89sgD8DXiOfrYpP_rl2Sa5scrPG4mRfNVMFs3kR83IXxighho</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2552839546</pqid></control><display><type>article</type><title>Overexpression of Special AT-Rich Sequence-Binding Protein 1 in Endometrial Cancer: A Clinicopathologic Study</title><source>MEDLINE</source><source>Journals@Ovid Complete</source><creator>Zhang, Yu ; Wang, Le ; Liu, Yunduo ; Meng, Fanling ; Wang, Shuxiang ; Shang, Pan ; Gao, Ya ; Chen, Xiuwei</creator><creatorcontrib>Zhang, Yu ; Wang, Le ; Liu, Yunduo ; Meng, Fanling ; Wang, Shuxiang ; Shang, Pan ; Gao, Ya ; Chen, Xiuwei</creatorcontrib><description>OBJECTIVESpecial AT-rich sequence-binding protein 1 (SATB1), as a genome organizer, serves important functions in tumor progression and metastasis. The SATB1 is overexpressed in various malignant tumors. However, the expression and prognostic value of SATB1 in endometrial cancer remain unknown. The aim of this study was to explore the prognostic values of SATB1 expression in endometrial cancer.
METHODS/MATERIALSWe investigated the expression of SATB1 in 172 untreated endometrial cancer tissues and 25 normal endometrial tissues through immunohistochemical staining. We also analyzed the association of SATB1 level with clinicopathologic parameters and determined its prognostic significance.
RESULTSpecial AT-rich sequence-binding protein 1 was expressed in 78 (45.3%) of the 172 endometrial cancer samples, but not in the normal endometrial samples. The positive expression of SATB1 was associated with clinicopathologic factors, such as International Federation of Gynecology and Obstetrics stage, histological grade, myometrial invasion depth, lymph node metastasis, vascular/lymphatic invasion, and recurrence. The patients with positive SATB1 expression had worse overall survival and disease-free survival rates than the patients with negative SATB1 expression (P < 0.001 for both). Multivariate Cox analysis indicated that SATB1 was an independent parameter for overall survival (hazards ratio, 2.928; 95% confidence interval, 1.072–7.994; P = 0.036) and disease-free survival (hazards ratio, 2.825; 95% confidence interval, 1.111–7.181; P = 0.029).
CONCLUSIONSResults showed that SATB1 may be involved in tumor development and progression in endometrial cancer, may serve as a promising biomarker for predicting the prognosis of endometrial cancer patients, and thus may act as a novel target for treating endometrial carcinoma.</description><identifier>ISSN: 1048-891X</identifier><identifier>EISSN: 1525-1438</identifier><identifier>DOI: 10.1097/IGC.0000000000000314</identifier><identifier>PMID: 25347096</identifier><language>eng</language><publisher>England: by the International Gynecologic Cancer Society and the European Society of Gynaecological Oncology</publisher><subject>Adult ; Aged ; Biomarkers, Tumor - metabolism ; Confidence intervals ; Endometrial cancer ; Endometrial Neoplasms - metabolism ; Endometrial Neoplasms - mortality ; Endometrial Neoplasms - pathology ; Female ; Follow-Up Studies ; Humans ; Immunoenzyme Techniques ; Lymphatic Metastasis ; Matrix Attachment Region Binding Proteins - metabolism ; Medical prognosis ; Metastasis ; Middle Aged ; Neoplasm Grading ; Neoplasm Invasiveness ; Neoplasm Recurrence, Local - metabolism ; Neoplasm Recurrence, Local - mortality ; Neoplasm Recurrence, Local - pathology ; Neoplasm Staging ; Prognosis ; Proteins ; Survival Rate ; Young Adult</subject><ispartof>International journal of gynecological cancer, 2015-01, Vol.25 (1), p.4-11</ispartof><rights>2015 by the International Gynecologic Cancer Society and the European Society of Gynaecological Oncology.</rights><rights>Copyright © 2014 by IGCS and ESGO2014</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3394-6be09afa9424a433b0dc883cd6849f452570fcb8dd3533c91a2d67858fbaa5b13</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25347096$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zhang, Yu</creatorcontrib><creatorcontrib>Wang, Le</creatorcontrib><creatorcontrib>Liu, Yunduo</creatorcontrib><creatorcontrib>Meng, Fanling</creatorcontrib><creatorcontrib>Wang, Shuxiang</creatorcontrib><creatorcontrib>Shang, Pan</creatorcontrib><creatorcontrib>Gao, Ya</creatorcontrib><creatorcontrib>Chen, Xiuwei</creatorcontrib><title>Overexpression of Special AT-Rich Sequence-Binding Protein 1 in Endometrial Cancer: A Clinicopathologic Study</title><title>International journal of gynecological cancer</title><addtitle>Int J Gynecol Cancer</addtitle><description>OBJECTIVESpecial AT-rich sequence-binding protein 1 (SATB1), as a genome organizer, serves important functions in tumor progression and metastasis. The SATB1 is overexpressed in various malignant tumors. However, the expression and prognostic value of SATB1 in endometrial cancer remain unknown. The aim of this study was to explore the prognostic values of SATB1 expression in endometrial cancer.
METHODS/MATERIALSWe investigated the expression of SATB1 in 172 untreated endometrial cancer tissues and 25 normal endometrial tissues through immunohistochemical staining. We also analyzed the association of SATB1 level with clinicopathologic parameters and determined its prognostic significance.
RESULTSpecial AT-rich sequence-binding protein 1 was expressed in 78 (45.3%) of the 172 endometrial cancer samples, but not in the normal endometrial samples. The positive expression of SATB1 was associated with clinicopathologic factors, such as International Federation of Gynecology and Obstetrics stage, histological grade, myometrial invasion depth, lymph node metastasis, vascular/lymphatic invasion, and recurrence. The patients with positive SATB1 expression had worse overall survival and disease-free survival rates than the patients with negative SATB1 expression (P < 0.001 for both). Multivariate Cox analysis indicated that SATB1 was an independent parameter for overall survival (hazards ratio, 2.928; 95% confidence interval, 1.072–7.994; P = 0.036) and disease-free survival (hazards ratio, 2.825; 95% confidence interval, 1.111–7.181; P = 0.029).
CONCLUSIONSResults showed that SATB1 may be involved in tumor development and progression in endometrial cancer, may serve as a promising biomarker for predicting the prognosis of endometrial cancer patients, and thus may act as a novel target for treating endometrial carcinoma.</description><subject>Adult</subject><subject>Aged</subject><subject>Biomarkers, Tumor - metabolism</subject><subject>Confidence intervals</subject><subject>Endometrial cancer</subject><subject>Endometrial Neoplasms - metabolism</subject><subject>Endometrial Neoplasms - mortality</subject><subject>Endometrial Neoplasms - pathology</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Humans</subject><subject>Immunoenzyme Techniques</subject><subject>Lymphatic Metastasis</subject><subject>Matrix Attachment Region Binding Proteins - metabolism</subject><subject>Medical prognosis</subject><subject>Metastasis</subject><subject>Middle Aged</subject><subject>Neoplasm Grading</subject><subject>Neoplasm Invasiveness</subject><subject>Neoplasm Recurrence, Local - metabolism</subject><subject>Neoplasm Recurrence, Local - mortality</subject><subject>Neoplasm Recurrence, Local - pathology</subject><subject>Neoplasm Staging</subject><subject>Prognosis</subject><subject>Proteins</subject><subject>Survival Rate</subject><subject>Young Adult</subject><issn>1048-891X</issn><issn>1525-1438</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNpdkU1PHSEUhklTU632HxhD0o2bURhgBtxdJ9aamGi8mnRHGGC8KAMjzNT674vRJo1ncc5ZPOfzBWAfoyOMRHt8cd4dof-NYPoJ7GBWswpTwj-XHFFecYF_bYOvOT8URtRIfAHbNSO0RaLZAePVb5vsnynZnF0MMA5wPVntlIer2-rG6Q1c26fFBm2rUxeMC_fwOsXZugAxLO4smDjaOb1WdKpg6QSuYOddcDpOat5EH--dhut5MS97YGtQPttv73EX3P04u-1-VpdX5xfd6rLShAhaNb1FQg1K0JoqSkiPjOacaNNwKgZaLmzRoHtuDGGEaIFVbZqWMz70SrEek11w-NZ3SrEsn2c5uqyt9yrYuGSJmzJGtKSpC_r9A_oQlxTKdrJmrOZEMNoU6uCdWvrRGjklN6r0Iv89sgD8DXiOfrYpP_rl2Sa5scrPG4mRfNVMFs3kR83IXxighho</recordid><startdate>201501</startdate><enddate>201501</enddate><creator>Zhang, Yu</creator><creator>Wang, Le</creator><creator>Liu, Yunduo</creator><creator>Meng, Fanling</creator><creator>Wang, Shuxiang</creator><creator>Shang, Pan</creator><creator>Gao, Ya</creator><creator>Chen, Xiuwei</creator><general>by the International Gynecologic Cancer Society and the European Society of Gynaecological Oncology</general><general>BMJ Publishing Group LTD</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>201501</creationdate><title>Overexpression of Special AT-Rich Sequence-Binding Protein 1 in Endometrial Cancer: A Clinicopathologic Study</title><author>Zhang, Yu ; Wang, Le ; Liu, Yunduo ; Meng, Fanling ; Wang, Shuxiang ; Shang, Pan ; Gao, Ya ; Chen, Xiuwei</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3394-6be09afa9424a433b0dc883cd6849f452570fcb8dd3533c91a2d67858fbaa5b13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Biomarkers, Tumor - metabolism</topic><topic>Confidence intervals</topic><topic>Endometrial cancer</topic><topic>Endometrial Neoplasms - metabolism</topic><topic>Endometrial Neoplasms - mortality</topic><topic>Endometrial Neoplasms - pathology</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Humans</topic><topic>Immunoenzyme Techniques</topic><topic>Lymphatic Metastasis</topic><topic>Matrix Attachment Region Binding Proteins - metabolism</topic><topic>Medical prognosis</topic><topic>Metastasis</topic><topic>Middle Aged</topic><topic>Neoplasm Grading</topic><topic>Neoplasm Invasiveness</topic><topic>Neoplasm Recurrence, Local - metabolism</topic><topic>Neoplasm Recurrence, Local - mortality</topic><topic>Neoplasm Recurrence, Local - pathology</topic><topic>Neoplasm Staging</topic><topic>Prognosis</topic><topic>Proteins</topic><topic>Survival Rate</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zhang, Yu</creatorcontrib><creatorcontrib>Wang, Le</creatorcontrib><creatorcontrib>Liu, Yunduo</creatorcontrib><creatorcontrib>Meng, Fanling</creatorcontrib><creatorcontrib>Wang, Shuxiang</creatorcontrib><creatorcontrib>Shang, Pan</creatorcontrib><creatorcontrib>Gao, Ya</creatorcontrib><creatorcontrib>Chen, Xiuwei</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of gynecological cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zhang, Yu</au><au>Wang, Le</au><au>Liu, Yunduo</au><au>Meng, Fanling</au><au>Wang, Shuxiang</au><au>Shang, Pan</au><au>Gao, Ya</au><au>Chen, Xiuwei</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Overexpression of Special AT-Rich Sequence-Binding Protein 1 in Endometrial Cancer: A Clinicopathologic Study</atitle><jtitle>International journal of gynecological cancer</jtitle><addtitle>Int J Gynecol Cancer</addtitle><date>2015-01</date><risdate>2015</risdate><volume>25</volume><issue>1</issue><spage>4</spage><epage>11</epage><pages>4-11</pages><issn>1048-891X</issn><eissn>1525-1438</eissn><abstract>OBJECTIVESpecial AT-rich sequence-binding protein 1 (SATB1), as a genome organizer, serves important functions in tumor progression and metastasis. The SATB1 is overexpressed in various malignant tumors. However, the expression and prognostic value of SATB1 in endometrial cancer remain unknown. The aim of this study was to explore the prognostic values of SATB1 expression in endometrial cancer.
METHODS/MATERIALSWe investigated the expression of SATB1 in 172 untreated endometrial cancer tissues and 25 normal endometrial tissues through immunohistochemical staining. We also analyzed the association of SATB1 level with clinicopathologic parameters and determined its prognostic significance.
RESULTSpecial AT-rich sequence-binding protein 1 was expressed in 78 (45.3%) of the 172 endometrial cancer samples, but not in the normal endometrial samples. The positive expression of SATB1 was associated with clinicopathologic factors, such as International Federation of Gynecology and Obstetrics stage, histological grade, myometrial invasion depth, lymph node metastasis, vascular/lymphatic invasion, and recurrence. The patients with positive SATB1 expression had worse overall survival and disease-free survival rates than the patients with negative SATB1 expression (P < 0.001 for both). Multivariate Cox analysis indicated that SATB1 was an independent parameter for overall survival (hazards ratio, 2.928; 95% confidence interval, 1.072–7.994; P = 0.036) and disease-free survival (hazards ratio, 2.825; 95% confidence interval, 1.111–7.181; P = 0.029).
CONCLUSIONSResults showed that SATB1 may be involved in tumor development and progression in endometrial cancer, may serve as a promising biomarker for predicting the prognosis of endometrial cancer patients, and thus may act as a novel target for treating endometrial carcinoma.</abstract><cop>England</cop><pub>by the International Gynecologic Cancer Society and the European Society of Gynaecological Oncology</pub><pmid>25347096</pmid><doi>10.1097/IGC.0000000000000314</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1048-891X |
| ispartof | International journal of gynecological cancer, 2015-01, Vol.25 (1), p.4-11 |
| issn | 1048-891X 1525-1438 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1639497362 |
| source | MEDLINE; Journals@Ovid Complete |
| subjects | Adult Aged Biomarkers, Tumor - metabolism Confidence intervals Endometrial cancer Endometrial Neoplasms - metabolism Endometrial Neoplasms - mortality Endometrial Neoplasms - pathology Female Follow-Up Studies Humans Immunoenzyme Techniques Lymphatic Metastasis Matrix Attachment Region Binding Proteins - metabolism Medical prognosis Metastasis Middle Aged Neoplasm Grading Neoplasm Invasiveness Neoplasm Recurrence, Local - metabolism Neoplasm Recurrence, Local - mortality Neoplasm Recurrence, Local - pathology Neoplasm Staging Prognosis Proteins Survival Rate Young Adult |
| title | Overexpression of Special AT-Rich Sequence-Binding Protein 1 in Endometrial Cancer: A Clinicopathologic Study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T15%3A38%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Overexpression%20of%20Special%20AT-Rich%20Sequence-Binding%20Protein%201%20in%20Endometrial%20Cancer:%20A%20Clinicopathologic%20Study&rft.jtitle=International%20journal%20of%20gynecological%20cancer&rft.au=Zhang,%20Yu&rft.date=2015-01&rft.volume=25&rft.issue=1&rft.spage=4&rft.epage=11&rft.pages=4-11&rft.issn=1048-891X&rft.eissn=1525-1438&rft_id=info:doi/10.1097/IGC.0000000000000314&rft_dat=%3Cproquest_pubme%3E2552839546%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2552839546&rft_id=info:pmid/25347096&rfr_iscdi=true |